We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Nasal Swab Test Detects Asthma Type in Kids

By LabMedica International staff writers
Posted on 06 Jan 2025

Asthma is the most prevalent chronic condition in children, with a particularly high impact on Black and Puerto Rican children. More...

It is crucial to develop new therapies to address the specific needs of these young patients. Traditionally, asthma has been categorized into endotypes: T2-high or T2-low, based on the levels of T helper 2 (T2) inflammation. More recently, the T2-low category has been further divided into two distinct subtypes: T17-high, characterized by increased T helper 17 (T17) inflammation and low T2 inflammation, and low-low, marked by low levels of both T2 and T17 inflammation. Given the variability of asthma, which is driven by different immune cells and responds to treatments in diverse ways, the first step toward improving therapies is accurate endotype diagnosis. Traditionally, diagnosing endotype involves a genetic analysis of lung tissue obtained through a bronchoscopy, a procedure performed under general anesthesia. However, for children, particularly those with milder asthma, this invasive approach is often impractical and unethical. As a result, clinicians have had to rely on less accurate tools, such as immune markers in the blood, lung function tests, and allergy presence.

Now, researchers at the University of Pittsburgh (Pittsburgh, PA, USA) have developed a non-invasive nasal swab test for children to diagnose specific asthma subtypes or endotypes. This approach promises to enable clinicians to prescribe treatments more precisely and could pave the way for research into therapies for less-studied asthma types that have been difficult to diagnose accurately. The study, published in JAMA, analyzed data from three independent U.S.-based studies, focusing on Puerto Rican and African American youth, who experience higher asthma rates and mortality compared to non-Hispanic white children.

The researchers collected nasal samples from 459 children across the three studies and analyzed the expression of eight T2 and T17 signature genes. As anticipated, the nasal swab analysis revealed the asthma endotype for each patient. Across the studies, 23% to 29% of participants were classified as T2-high, 35% to 47% as T17-high, and 30% to 38% as low-low endotype. While biologic drugs that target immune cells driving T2-high asthma are available, there are no current biologic treatments for T17-high and low-low endotypes. With the availability of this simple nasal swab test to detect other endotypes, the focus can now shift on developing biologics for T17-high and low-low disease. This rapid diagnostic test could also accelerate progress in other areas of asthma research.

“One of the million-dollar questions in asthma is why some kids get worse as they enter puberty, some stay the same and others get better. Before puberty, asthma is more common in boys, but the incidence of asthma goes up in females in adulthood,” said senior author Juan Celedón, M.D., Dr. P.H., professor of pediatrics at Pitt. “Is this related to endotype? Does endotype change over time or in response to treatments? We don’t know. But now that we can easily measure endotype, we can start to answer these questions.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.